Abstract
The Centers for Medicare & Medicaid Services has approved FDG PET imaging and reimburses for its use in the following oncologic applications: Initial diagnosis, staging, and restaging for colorectal cancer, non–small cell lung cancer, lymphoma, esophageal cancer, head and neck cancer, and melanoma; Staging and restaging for breast and cervical cancer; Evaluation of malignant potential for a solitary pulmonary nodule; and Evaluation of papillary thyroid cancer that has been shown to be non-iodine-avid. These specific oncologic indications are the focus of this discussion, although PET imaging may be useful for the evaluation of many other types of cancer, and indications may be liberalized in the near future. The reader is directed to the literature for discussion of protocols and normal variants of PET imaging. Excellent comprehensive reviews of PET oncologic imaging are available.1–8
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
